Lenvima (lenvatinib; Eisai/Novartis/Merck & Co) is an orally available small molecule inhibitor of multiple tyrosine kinases including vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR).
Isentress (raltegravir; Merck & Co) is a twice-daily, unboosted integrase inhibitor (INI) that is used in combination with other antiretroviral drugs for treatment of HIV-1 infection.
Invanz (ertapenem; Merck & Co) is a carbapenem antibacterial agent that inhibits bacterial cell wall synthesis through binding to penicillin-binding proteins. The drug inhibits the crosslinking of…
Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate [TAF]; Gilead) is a single-tablet regimen (STR) approved for the treatment of HIV-1 infection.
Ganetespib, under development by Synta, is a small molecule inhibitor of HSP90. HSP90 is a chaperone protein required to drive growth, proliferation, and cell survival in tumor tissue.
F/TAF (emtricitabine/tenofovir alafenamide fumarate [TAF]; Gilead) is a fixed-dose combination of two of Gilead’s nucleoside reverse transcriptase inhibitors, Emtriva (emtricitabine) and GS-7340 (TAF).
In 1995, GlaxoSmithKline’s Flolan (epoprostenol) became the first therapy to be specifically approved for the orphan disease of pulmonary arterial hypertension (PAH).
Factive (gemifloxacin mesylate; Vansen Pharma) is an oral synthetic broad-spectrum antibacterial agent related to the fluoroquinolone class of antibiotics.
DPIV is a tetravalent, AS03B-adjuvanted, purified formalin-inactivated dengue virus vaccine being developed by GlaxoSmithKline in collaboration with the US Walter Reed Army Institute of Research and the Oswaldo Cruz Foundation in Brazil.
The US Naval Medical Research Center (NMRC) is developing a Vaxfectin (cationic lipid-based adjuvant; Vical)-adjuvanted, tetravalent plasmid DNA vaccine.
This product profile relates to the mesalamine franchise that covers Delzicol (mesalamine; Actavis), Asacol (mesalamine; Zeria/Kyowa Hakko Kirin), and Asacol HD (mesalamine; Actavis/Zeria)…
Delafloxacin is a novel broad-spectrum fluoroquinolone that prevents bacterial DNA synthesis through its equal inhibitory effect against the enzymes topoisomerase II (DNA gyrase) and IV.
DCVAC/PCa is a cell-based cancer vaccine composed of autologous dendritic cells which are activated to recognize a prostate cancer cell line. When infused into patients, the primed dendritic cells cause activation of T cells…
D/C/F/TAF is a once-daily single-tablet regimen (STR) combination of the protease inhibitor (PI) Prezista (darunavir; Johnson & Johnson), the two nucleoside reverse transcriptase inhibitors…
Dalvance is a second-generation, semi-synthetic lipoglycopeptide antibacterial compound of the same class as vancomycin. The drug inhibits the formation of, and disrupts the integrity of…
Beraprost (United Therapeutics/Astellas/Kaken Pharmaceutical Co) is an oral chemically stable prostacyclin analog targeting the prostaglandin I2 (PGI2) receptor…
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!